Neoss Launches NeoGenix XP™

Safe and Clinically Proven Natural Bone Substitute

Following the successful and well-received Allograft line, Neoss is excited to announce the addition of NeoGenix XP™ this autumn to our existing product portfolio.

NeoGenix XP™ is a safe and clinically proven natural bone substitute, that closer resembles natural bone than those of synthetic materials, such as hydroxyapatite or tricalcium phosphate.

Surface roughness affects cellular response, enhancing cell adhesion and proliferation and possibly other markers of expression of cell phenotype, like production of collagen type I, osteocalcin, extracellular matrix, and mineralized material.

“Being a strong partner to our customers has always been important and offering more in terms of total package solutions. NeoGenix XP™ is an important addition to this and strengthens not only the bone regeneration portfolio but will allow us to serve our customer even better!” —Dr Robert Gottlander, Neoss CEO

This exciting product line will add new dimensions to Neoss existing Bone Regeneration offering, providing an enhanced offering of Bone materials and membranes.

Neoss maintains its clear focus on innovation and has a continuous plan of new market leading product solutions that will be presented over the next few years. All with the same target of introducing smart products that are intuitively easy to use with Intelligent Simplicity.

More here.

 

SourceNeoss®

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”